德谷胰岛素利拉鲁肽注射液治疗初发2型糖尿病患者的临床效果分析  

Analysis of the Clinical Effect of Degu Insulin and Lilalutide Injection in the Treatment of Newly Diagnosed Type 2 Diabetes Patients

作　　者：赵情 ZHAO Qing(Department of Endocrinology,Xinyi People's Hospital,Xinyi,Jiangsu,221400,China)

机构地区：[1]新沂市人民医院内分泌科,江苏新沂221400

出　　处：《中外医疗》2024年第29期115-118,共4页China & Foreign Medical Treatment

摘　　要：目的分析德谷胰岛素利拉鲁肽注射液治疗初发2型糖尿病患者的临床效果。方法方便选取2022年1月—2024年1月新沂市人民医院收治的128例2型糖尿病患者作为研究对象,依据不同治疗方法分为对照组和观察组,各64例。对照组予以德谷门冬双胰岛素治疗,观察组予以德谷胰岛素利拉鲁肽注射液治疗,比较两组患者治疗前、后的血糖水平、体质指数、胰岛素用量以及低血糖发生率。结果治疗后,两组患者血糖水平均低于治疗前,且观察组空腹血糖为(5.62±1.69)mmol/L、餐后2 h血糖(6.54±1.72)mmol/L、糖化血红蛋白为(6.09±0.82)%,低于对照组的(6.57±1.74)mmol/L、(7.42±1.84)mmol/L、(7.33±0.94)%,差异有统计学意义(t=3.133、2.795、3.463,P均<0.05)。治疗后,两组患者体重指数低于治疗前,且观察组低于对照组,差异有统计学意义(P均<0.05)。观察组胰岛素用量、低血糖发生率低于对照组,差异有统计学意义(P均<0.05)。结论德谷胰岛素利拉鲁肽注射液可以更好地控制患者的血糖并有助于降低体重指数、胰岛素用量及低血糖发生率,可作为有效药物选择。Objective To analyze the clinical effect of Degu insulin and Lilalutide injection in the treatment of newly diagnosed type 2 diabetes patients.Methods 128 patients with type 2 diabetes who were admitted to Xinyi People's Hospital from January 2022 to January 2024 were conveniently selected as the study objects and divided into control group and observation group according to different treatment methods,with 64 cases in each group.The control group was treated with Degu aspartate double insulin,and the observation group was treated with Degu insulin Liraglutide in⁃jection.The blood glucose level,body mass index,insulin dosage and incidence of hypoglycemia were compared be⁃tween the two groups before and after treatment.Results After treatment,the blood glucose level in both groups was lower than before treatment,and the fasting blood glucose in observation group was(5.62±1.69)mmol/L,the blood glu⁃cose 2 h after meal was(6.54±1.72)mmol/L,and the glycosylated hemoglobin was(6.09±0.82)%,lower than(6.57±1.74)mmol/L,(7.42±1.84)mmol/L,(7.33±0.94)%of control group,the differences were statistically significant(t=3.133,2.795,3.463,all P<0.05).After treatment,the body mass index of the two groups was lower than before treat⁃ment,and the observation group was lower than the control group,the differences were statistically significant(all P<0.05).The dosage of insulin and incidence of hypoglycemia in observation group were lower than those in control group,and the differences were statistically significant(both P<0.05).Conclusion Liraglutide injection can better con⁃trol the blood glucose of patients and help to reduce the body mass index,insulin dosage and the incidence of hypogly⁃cemia,which can be an effective drug choice.

关 键 词：2型糖尿病 德谷胰岛素利拉鲁肽注射液 血糖水平 低血糖发生率 体重指数 

分 类 号：R587.1[医药卫生—内分泌]